<DOC>
	<DOCNO>NCT01947907</DOCNO>
	<brief_summary>A six month study ACP-001 , long-acting growth hormone product , versus standard human growth hormone therapy . ACP-001 give once-a-week , standard human growth hormone ( hGH ) give daily basis . The primary aim demonstrate safety , pharmacokinetics pharmacodynamics period six month . A secondary objective comparison height velocity ( HV ) ACP-001 treat group daily hGH treatment group .</brief_summary>
	<brief_title>Safety , PK/PD ( Pharmacokinetics/Pharmacodynamics ) Efficacy ACP-001 Weekly Versus Daily hGH Children With Growth Hormone Deficiency ( GHD )</brief_title>
	<detailed_description />
	<mesh_term>Endocrine System Diseases</mesh_term>
	<mesh_term>Dwarfism , Pituitary</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<criteria>Prepubertal child , Tanner stage 1 Diagnosis GHD , confirm two stimulation test Bone age great chronological age Impaired height height velocity BMI within +/ 2 SD ( standard deviation ) Baseline IGF1 ( insulinlike growth factor ) Normal fundoscopy Stable hormonal replacement therapy ( hGH ) Written Informed Consent Prior exposure rhGH IGFI Past present intracranial tumor ; history presence malignant disease Small gestational age ( SGA ) Malnutrition Psychosocial dwarfism Coeliac disease AntihGH antibodies Diabetes mellitus Chromosomal abnormality ( e.g . Turner syndrome , SHOX ) Closed epiphysis Known suspect HIV infection</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>12 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Human Growth Hormone</keyword>
	<keyword>rhGH</keyword>
	<keyword>hGH</keyword>
	<keyword>GHD</keyword>
</DOC>